1. INTRODUCTION {#sec1}
===============

Cellular communication is a key feature of evolution. The multitude of stimuli that can reach a cell may elicit different cellular responses according to the signalling pathways present in the cell. In addition, there may exist a cross-communication between these signalling pathways which is crucial for the fine-tuning of cellular response. The first interaction or crosstalk process can take place at the surface receptor level \[[@r1]\]. The crosstalk between two given pathways can modify not only the response to their corresponding specific signals (ligands) but also their regulation (*e.g*. desensitization). This crosstalk can be only functional (no direct contact exists between signalling components) or can involve a direct association, mainly at the receptor level through di/oligomerization \[[@r2]\]. G protein-coupled receptors (GPCRs) transduce a diversity of extracellular signals and regulate virtually every aspect of physiology, however, their overstimulation can be harmful, resulting in cellular toxicity or uncontrolled cellular growth. Therefore, different *desensitization* (decrease in response to repeated or continuous stimulation) mechanisms have been developed to avoid such overstimulation, involving a network of kinases, ubiquitin ligases, and adaptor proteins acting on GPCRs \[[@r3]\]. GPCR-mediated transduction pathways can be modulated by the interaction between different receptors. In fact, oligomerization exerts a significant impact on receptor function and physiology which contributes to increasing the diversification of receptor signalling, pharmacology, regulation, crosstalk, internalization and trafficking \[[@r4], [@r5]\].

GPCR signalling can be modulated not only by ligand binding to orthosteric sites of receptors but also by binding to allosteric sites, which are involved in the affinity and selectivity of ligands for GPCRs and represent a promising target for the design of new drugs to treat disorders of the central nervous system through GPCR activation/blockade \[[@r6]\]. Moreover, the formation of hetero-oligomers may provide novel allosteric binding pockets for ligand binding and new targeting possibilities \[[@r7]\].

Adenosine is an endogenous purinergic nucleoside present in all cells where forms part of the nucleic acids and the energy currency of life, ATP. Furthermore, adenosine is also able to act as signalling molecule through binding adenosine receptors (ARs) which belong to class A GPCR superfamily being linked, therefore, to different transduction mechanisms including adenylate cyclase (AC), phospholipase C (PLC), phospholipase A~2~, phospholipase D and G protein-coupled inwardly-rectifying potassium channels (GIRK). ARs have been further subdivided into four main types (A~1~, A~2A~, A~2B~ and A~3~) according to pharmacological profile, functional coupling to adenylyl cyclase activity and tissue distribution. Thus, A~1~ and A~3~ receptors inhibit AC through G~i/o~ proteins whereas A~2A~ and A~2B~ receptors stimulate AC through G~s~ proteins. ARs are widely expressed throughout the body where they participate in physiological processes such as immune function, heart rate and circulation, lipolysis, sleep regulation, and angiogenesis \[[@r8]\]. GPCRs dimerization is also an important research field in adenosine receptors \[[@r9], [@r10]\] and can be involved in physiological and pathological processes by homo- and heteromerization processes. Thus, adenosine receptors can interact with each other and with different GPCRs such as A~1~/A~2A~, A~2A~/CB~1~, A~2A~/CB~1~/D~2~, A~2A~/mGlu~5~, or A~2A~/D~2~ \[[@r4]\]. This heterodimerization can be modulated by purines and xanthines such as caffeine and theophylline \[[@r11]\]. Even A~1~/A~2A~, A~2A~/D~2~, A~2A~/mGlu~5~ heterodimers and A~2A~/mGlu~5~/D~2~ heterotrimers have been related to Alzheimer disease \[[@r12], [@r13]\].

L-glutamate is a naturally occurring aminoacid widely known to be the main excitatory neurotransmitter in the Vertebrate Central Nervous System although its actions reach peripheral and non-neural tissues such as adrenal gland, pancreas, immune cells and a large etcetera \[[@r14]\]. Glutamate actions are mediated by a group of membrane receptors named glutamate receptors which include metabotropic (mGlu) and ionotropic (iGlu) glutamate receptors. MGlu receptors also belong to class C GPCR superfamily and have been subclassified into three groups: Group I (mGlu~1~ and mGlu~5~) which stimulate PLC activity through a G~q/11~ protein, Group II (mGlu~2~ and mGlu~3~) and Group III (mGlu~4~, mGlu~6~, mGlu~7~ and mGlu~8~) which inhibit AC activity through a G~i/o~ protein \[[@r15]\]. iGlu receptors are ligand-gated ion channels involved in fast excitatory neurotransmission and which include AMPA, NMDA and Kainate receptors according to the response to agonist.

One of the most relevant functions of adenosine in Nervous System is to regulate synaptic transmission. This neuromodulatory action is possible thanks to a combination of effects at presynaptic and postsynaptic levels that permits adenosine to influence both the release of several neurotransmitters, including L-glutamate, and also regulate neurotransmitter action \[[@r16]\]. The neuromodulatory role of adenosine is mainly linked to A~1~ and A~2A~ receptors since both are predominant in brain. In fact, A~1~ receptor is the most abundant and widespread in the brain whereas A~2A~ receptors are concentrated in the basal ganglia although they can also be found throughout the brain at lower densities. Concerning synaptic localization, both receptors are mainly distributed at presynaptic regions but they have been also detected at postsynaptic membranes \[[@r17]\]. Thus, ultrastructural analysis has demonstrated the A~2A~ receptors postsynaptic localization in the dendrites and dendritic spines of GABAergic neurons in rat striatum \[[@r18]\]. In contrast, hippocampal A~2A~ receptors are mostly located in nerve terminals and particularly in the presynaptic active zone \[[@r19]\]. Striatal A~2A~ immunoreactivity has been observed primarily at glutamatergic synapses, predominantly at the postsynaptic but also at the presynaptic site \[[@r18], [@r20]\]. This localization of A~2A~ receptors is in line with its suggested role in the fine-tuning modulation of glutamatergic neurotransmission in striatal GABAergic neurons both at the postsynaptic and presynaptic level \[[@r18], [@r20]-[@r21]\]. Moreover, A~2A~, mGlu~5~ and D~2~ receptors do oligomerize in GABAergic striatopallidal neurons, and these receptors co-distributed in postsynaptic structures along the extrasynaptic and perisynaptic plasma membrane of spines, establishing asymmetrical, putative glutamatergic, synapses with axon terminals \[[@r22]\]. Thus, although striatal A~2A~ receptors are mostly located postsynaptically, they are also present in the presynaptic active zone. Conversely, although A~2A~ receptors are mostly located presynaptically in the hippocampus, they are also present in the postsynaptic density. Accordingly, A~2A~ receptors are able to modulate the release of neurotransmitters (GABA, acetylcholine and glutamate) in the striatum, whereas they are able to control postsynaptic responsiveness in the hippocampus \[[@r19]\]. This pre- and post-synaptic presence A~2A~ receptors has been also reported in monkey basal ganglia, with a high degree of colocalization between A~2A~ and mGlu~5~ in dendrites and spines of striatal neurons where they functionally interact \[[@r23]\].

The excitatory neurotransmitter L-glutamate can also act as neuromodulator through binding mGlu receptors which are widely distributed throughout the CNS where they specifically localize in both synaptic and extrasynaptic regions. In general, group I-mGlu receptors are frequently found at postsynaptic regions, but also located presynaptically \[[@r24], [@r25]\], and their activation often increases neuronal excitability whereas group II and group III mGlu receptors are mainly distributed on presynaptic terminals where they can inhibit neurotransmitter release at both inhibitory (GABAergic) and excitatory (glutamatergic) synapses \[[@r26], [@r27]\].

2. FUNCTIONAL INTERACTION BETWEEN ADENOSINE AND mGlu RECEPTORS {#sec2}
==============================================================

In recent decades, the functional interaction between adenosine and metabotropic glutamate receptors has received a great deal of attention in the GPCR field. Most of these studies have been carried out in cells from Central Nervous System using both *in vivo* and *in vitro* approaches. The results of these studies have indicated that the *crosstalk* between the two groups of receptors took place at multiple levels including second messenger production, synaptic transmission, neurotransmitter release and behavioural effects. In the present review, we will focus on group I mGlu /adenosine receptor interactions, although there are also data showing the functional interaction between group II/III mGlu and adenosine receptors \[[@r28], [@r29]\].

2.1. Adenosine A~1~ and Metabotropic Glutamate Receptors Cross-talk {#sec2.1}
-------------------------------------------------------------------

Ogata and coworkers showed the first evidence of a crosstalk process between both groups of receptors in 1994 using cultured type 1 astrocyte from the hippocampus. They observed that the activation of A~1~ receptor potentiated group I mGlu receptor-mediated calcium responses. Two years later, the same research group also described the opposite crosstalk showing that the accumulation of cAMP induced by the nonselective adenosine receptor agonist, 2-chloroadenosine, was potentiated by different agonists of group I mGlu receptors \[[@r28], [@r30]\]. The utilization of more selective receptor ligands allowed the study of the functional interaction with more precision. Thus, Toms and Roberts (1999) \[[@r31]\], by using DHPG, a selective group I mGlu receptor agonist, described how A~1~ receptor activation potentiated DHPG-evoked intracellular calcium responses in cultured cortical type 2 astrocytes. In line with this, Ciruela and coworkers (2001) \[[@r32]\] by using co-transfected HEK-293 cells with the cDNAs for mGlu~1a~ and A~1~ receptors showed that the activation of mGlu~1a~ potentiated the calcium peak obtained in response to A~1~ activation. Similarly, they also found that A~1~ receptor activation increased the calcium responses induced by mGlu~1~ activation. Inhibitory interactions between the two groups of receptors have also been reported. Thus, the measurement of intracellular cAMP in several clones with inducible expression of A~1~ and mGlu~1~ receptors (HEK293am cells) revealed that mGlu~1~ activation decreased A~1~ receptor signalling measured as adenylate cyclase inhibition \[[@r33]\] whereas the activation of the A~1~ receptor in Purkinje cells lead to the depression of mGlu~1~-evoked calcium responses.

*In vivo* experiments also revealed the functional interaction between mGlu and adenosine receptors in rodent models. Thus, our research group showed that chronic subcutaneous injection of R-N^6^- phenylisopropiladenosine (R-PIA), a selective A~1~ receptor agonist, for 6 days in male rats evoked an increase in group I-mGlu receptors functionality which was also accompanied by an up-regulation of mGlu receptor number \[[@r34]\]. Chronic oral consumption of R-PIA during gestation also altered group I-mGlu receptor functionality in plasma membrane from the maternal brain. However, in this case, we observed a significant decrease of mGlu~1~ and mGlu~5~ receptors and a corresponding desensitization of mGlu receptor/PLC signalling pathway \[[@r35]\] which suggest that crosstalk processes may be influenced by different parameters such as gender or routes of administration. In reciprocal experiments, continuous L-glutamate intake throughout gestation also decreased A~1~ receptor/AC signalling pathway in the maternal brain \[[@r36]\]. Finally, we have observed not only changes in group I-mGlu receptors functionality upon prolonged exposure to A~1~ receptor agonist but also we showed a loss of group I-mGlu receptors responsiveness following chronic caffeine exposure which suggests that the blockade of adenosine receptors might also alter mGlu receptor functionality \[[@r37]\].

There are multiple works showing a negative interaction between A~1~ and mGlu~1~ receptors at the level of synaptic transmission. Thus, Tabata and coworkers (2007) showed that the activation of A~1~ depressed mGlu~1~ signalling measured as mGlu~1~-coupled inward cation current and mGlu~1~-coupled calcium release from intracellular stores in Purkinje cells \[[@r38]\]. Similarly, Kamikubo and coworkers (2013) also demonstrated that the activation of A~1~ in cultured mouse Purkinje cells blocked mGlu~1~-mediated long-term depression of glutamate-responsiveness \[[@r39]\]. Reciprocal negative interaction between mGlu and A~1~ receptors has also been demonstrated in: (1) cerebrocortical synaptosomes where an agonist of group I/II mGlu receptors suppressed the inhibitory action of A~1~ on glutamate release \[[@r40]\]; and (2) in rat hippocampal slices where electrophysiological recordings showed that the activation of mGlu~1a~ suppressed A~1~-mediated responses \[[@r41]\].

2.2. Adenosine A~2~ and Metabotropic Glutamate Receptors Cross-talk {#sec2.2}
-------------------------------------------------------------------

A positive interaction between A~2A~ and mGlu~5~ receptors has been demonstrated in the ventral striatopallidal pathway, striatum and hippocampus where the activation of A~2A~ in the nucleus accumbens and in glutamatergic nerve terminals of the rat striatum facilitated GABA and L-glutamate release, respectively \[[@r27], [@r42]\]. On the other hand, in neostriatal slices, both receptors acted in a synergistic way by phosphorylating DARPP-32 \[[@r43]\]. Interestingly, there are no data reporting functional interaction at the level of the second messenger between A~2A~ and mGlu~5~ receptors although complexes containing A~2A~ and mGlu~5~ have been described in heterologous systems and in native tissues and functional interaction has also been revealed on ERK 1/2 phosphorylation, c-fos expression and neurotransmitter release \[[@r44]\]. The synergy between A~2A~ and mGlu~5~ also affect other receptors such as NMDA receptor or dopamine D~2~ receptor (D~2~R). In the case of NMDA receptor, it was described how adenosine A~2A~ enhanced mGlu~5~-mediated potentiation of NMDA effects in the striatum and hippocampus \[[@r45], [@r46]\]. Concerning D~2~R, both receptors acted synergistically to reduce the affinity of D~2~R and to modulate D~2~R-mediated control of striatopallidal GABA neurons \[[@r47], [@r48]\].

Striatal region plays a fundamental role in motor and in reward, motivation and drug-seeking behaviour. As shown above, there are multiple works reporting a functional interaction between A~2A~ and mGlu~5~ receptors in the striatum. It is reasonable that the interaction between the two groups of receptors at a behavioural level has been focused on animal models of Parkinson disease (PD) and in abuse drug-induced mechanisms. Thus, Coccurello and coworkers (2004) observed that perfusion of 6-hydroxydopamine in the striatum of rats produced akinetic deficits \[[@r49]\]. These deficits were not abolished when rats were treated with a non-effective dose of MPEP, a selective mGlu~5~ antagonist. Similar results were found when hydroxydopamine rats were exposed to a non-effective dose of CSC, a selective A~2A~ antagonist. However, coadministration of both antagonists promoted a full recovery of akinesia demonstrating a behavioural interaction between A~2A~ and mGlu~5~. Kachroo and coworkers (2005) also found that a simultaneous blockade of A~2A~ and mGlu~5~ receptors acutely stimulates motor activity in a synergistic way in parkinsonian mice \[[@r50]\]. Interestingly, authors reinforced the importance of developing novel and efficient dual antagonist in order to avoid that the basal activity of mGlu~5~ may hamper the antiparkinsonian potential of A~2A~ antagonist administered alone.

Concerning the role of A~2A~-mGlu~5~ interactions in drug-seeking behaviour, Brown and coworkers (2012) showed that this interaction participates in mediating the conditioned effects of cocaine but not cocaine-induced hyperactivity \[[@r51]\]. Thus, by using a combination of pharmacological and genetic approaches, authors found that the selective mGlu~5~ antagonist MTEP prevented cocaine-conditioned place preference in wild-type mice but failed in A~2A~ KO mice. The functional interactions between A~2A~ and mGlu~5~ have also been shown to regulate alcohol-seeking in a rodent model of alcohol use. Thus, a combination of subthreshold doses of MTEP, mGlu~5~ antagonist, and SCH 58261, A~2A~ antagonist, induced a higher reduction in alcohol-self administration compared to vehicle or either antagonist alone \[[@r52]\]. Finally, the interaction A~2A~-mGlu~5~ has also been shown to modulate the locomotor, stereotypic and drug-seeking effect of methamphetamine. In this case, authors also used a combination of subthreshold doses of MTEP and SCH 58261 and found that antagonist combination prevented methamphetamine-induced locomotor and stereotypic rearing responses and methamphetamine-seeking behaviors \[[@r53]\].

3. POSSIBLE MECHANISMS OF CROSSTALK BEHIND FUNCTIONAL INTERACTION {#sec3}
=================================================================

In general, the mechanisms through which adenosine and mGlu receptors interact are poorly investigated. We present here a range of mechanisms suggested to participate in some of the functional interactions described in the above paragraphs, including direct association of receptors (di/oligomerization), phosphorylation by second-messengers dependent protein kinases (*e.g*. protein kinase A or PKA, protein kinase C or PKC), and sharing of G proteins or other cytoskeletal and/or adaptor proteins.

A signalling pathway can be considered as a succession of interactions between proteins that result in the generation of a cellular response. Such interactions must occur in an orderly and coordinated way, otherwise the normal functioning of the cellular signalling would be lost, probably leading to diseases such as cancer or Alzheimer's. These interactions are part of the so-called *interactomics* of the cell. Protein--protein interactions are the physical contacts of high specificity established between two or more proteins as a result of biochemical events steered by electrostatic forces including the hydrophobic effect \[[@r54]\]. These interactions may last a short time or a long time, or be the basis of the formation of macromolecular complexes.

It is easy to imagine that thousands of interactions between different proteins can occur in the interior of a cell and that to generate a list of all of them can be a huge work. The combination of the available data about these interactions, not only between proteins but between the different components of a cell, generates such a large quantity of data that it becomes necessary (essential) to develop large databases and the appropriate tools to access meaningful data. In fact, availability and accessibility of these databases to the scientific community are increasing. Sometimes the information is redundant, that is, there is not a single database in which all these interactions are collected, but at least several of them can be combined to obtain the most relevant information available. In line with this, The Proteomics Standard Initiative Common QUery InterfaCe (PSICQUIC) specification was created by the Human Proteome Organization Proteomics Standards Initiative (HUPO-PSI) in 2008. Its web service provides computational access to molecular-interaction data resources. The PSICQUIC protein interaction datasets are accessible directly from the Cytoscape molecular interaction network tool, allowing users to select the interaction data from all or a subset of the datasets available. In the present review, we used Cytoscape 3.5.1 tool, an open source software platform for visualizing molecular interaction networks and biological pathways and integrating these networks with annotations, gene expression profiles and other state data \[[@r55]\]. Through its *Universal Interaction Database Client* searching tool, we collected data about interactions where any of the receptors reviewed here were involved. Other database sources of protein interactions were manually browsed. All of them have been summarized in Table **[1](#T1){ref-type="table"}**.

It must be noted that many of adenosine and mGlu receptor proteins reviewed here can be identified with more than one name (Table **[2](#T2){ref-type="table"}**). Therefore, searching started with the 'official' proposed name (UniProt ID) but its synonyms (see [www.uniprot.org](http://www.uniprot.org)) were also employed to browse databases, including Worldwide Protein Data Bank (<https://www.wwpdb.org>) \[[@r56]\].

3.1. Direct Interaction between Adenosine and Meta-botropic Glutamate Receptors {#sec3.1}
-------------------------------------------------------------------------------

The protein-protein interactions have been studied by different methodological approaches and many of them can be recovered from the public online databases cited above. [Fig. (**[1](#F1){ref-type="fig"}**)](#F1){ref-type="fig"} shows a direct interactions network established between adenosine and group I metabotropic glutamate receptors in *Homo sapiens*, according to available scientific data, that could contribute to the *crosstalk* modulation reviewed herein (Table **[3](#T3){ref-type="table"}**). These direct interactions have also been reported in *Rattus norvegicus*; even a direct interaction between rat mGlu~5~ and human A~2A~ has been detected, probably due to a conserved structure in the latter receptor with respect to their homologue in the rat.

GPCRs function can be the result of their individual (monomer state) and/or aggregated activation (oligomerized state). This oligomerization with themselves (*homomers*) or different receptors (*heteromers*) can modulate its pharmacology and functionality \[[@r5]\]. Different experimental techniques have been devised to study GPCR oligomerization, which was deeply reviewed elsewhere \[[@r57]\]. GPCR homomers, mainly dimers, seems to be a more generalized feature for GPCR than expected \[[@r58]\]. In fact, several adenosine and metabotropic glutamate receptors are now known to form homodimers \[[@r59], [@r60]\], Moreover, such dimerization processes could be a key determinant of their activation and function. It has been proposed that mGlu receptors must be in a homodimer state to be activated by glutamate, as reported when a full-length mGlu~2~ receptor was purified, reconstituted, and stabilized in a native-like environment \[[@r61]\]. This preferential formation of mGlu receptors homodimers at the surface of cells has been also reported by using a time-resolved Förster resonance energy transfer (trFRET) combined with SNAP-tag technology \[[@r62], [@r63]\] and by photobleaching experiments using GFP labeled mGlu receptors \[[@r64]\]. Higher order structures (*e.g*. dimers of dimers) seems to be very transient, as they have only been detected in the case of mGlu~2~ when their interaction was stabilized by a disulfide bridge \[[@r65]\].

In turn, the formation of heteromers probably represents the easiest way through which different GPCRs can interact with them. Heterologous expression studies revealed that group I mGlu receptors on one hand, and group II and III mGlu receptors, on the other hand, could form heterodimers \[[@r63]\], increasing to 16 the number of additional mGlu receptors with likely specific pharmacological and functional properties.

The combination of co-immunoprecipitation, Western-blotting and immunocytochemical assays revealed that mGlu~1a~ and A~1~ assembled into functionally interacting complexes in rat cerebellum and in HEK-293 cells \[[@r32]\]. Similarly, co-immunoprecipitation, immunofluorescence and FRET assays also showed that A~1~ and mGlu~1~ receptors formed a complex in HEK293am cells \[[@r33]\]. The formation of this complex has been suggested to participate in the *crosstalk* process in which the activation of mGlu~1~ inhibited A~1~ functionality, measured as inhibition of forskolin-stimulated cAMP accumulation \[[@r33]\]. A~1~ heteromerize with mGluR~1a~, resulting in the modulation of glutamate cytotoxicity, while A~2A~ functionally interacts with mGlu~5~ in the striatum, as supported by studies in cotransfected cells and knockout mice \[[@r9], [@r53], [@r66]\] but also in native rat striatum \[[@r22], [@r27]\].

3.2. Functional Cross-talk through the G-proteins {#sec3.2}
-------------------------------------------------

Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Gα-subunits are divided into four families: Gα~s~, Gα~i/o~, Gα~q/11~ and Gα~12/13~. The Gα~s~ and Gα~i/o~ families activate or inhibit the activity of adenylate cyclase, respectively. The Gα~q/11~ family stimulates phospholipase C (PLC). Finally, the Gα~12/13~ family activates small GTPases including the Rho family (*e.g*., RhoA) \[[@r67]\]. Thus, mGlu~2~ and mGlu~4~, two receptors negatively coupled to adenylyl cyclase, its canonical pathway, are able to activate PLC, its non-canonical pathway, when coexpressed with the G proteins Gα~15~ or Gα~q~ \[[@r68]\]. In ON bipolar neurons from retina Gα~o1~ mediates mGlu~6~ signalling \[[@r69]\]. Adenosine A~1~ receptor also needs Gα~o1~ binding to form the ternary complex between agonist, receptor, and G protein \[[@r70]\]. Another mechanism proposed that involves G protein was described in retinotectal transmission where both A~1~ receptor and group II mGlu receptors mediated presynaptic inhibition at the retinotectal synapse of goldfish by sharing a Gα~i~ protein. For that reason, when both groups of receptors were simultaneously activated the inhibitory effects on synaptic transmission were not additive but occluded each other \[[@r29]\]. The interaction with and the activation of these G proteins by GPCRs is a regulated process. Thus, a regulator of G-protein signalling 12 (RGS12)

inhibits signal transduction by increasing the GTPase activity of Gα subunits, thereby driving them into their inactive GDP-bound form. RGS12 interacts with Gα~i1~ \[[@r71]\], and surface plasmon resonance analysis of RGS12 PDZ domain binding specificity has revealed its interaction with mGlu~1~, mGlu~2~ and mGlu~5~ receptors \[[@r72]\].

Not only can Gα-subunits mediate *crosstalk* processes between GPCRs. G protein βγ subunits have been also proposed as mediators of the enhanced group I mGlu-evoked \[Ca^2+^\] responses observed in type 2 astrocytes when adenosine A~1~ receptors are co-activated \[[@r31]\], suggesting that phospholipase C activity could be increased by G protein βγ subunits although the precise mechanism was not investigated. However, other reported *crosstalk* processes seem to be G protein-independent. Thus, Tabata and coworkers (2007) by using a perforated-patch voltage-clamp technique in cerebellar Purkinje cells showed that A~1~ activation induced a continuous depression of mGlu~1~ \[[@r38]\]. This interaction did not require Gα~i/o~ proteins. Finally, it has also been reported that mGlu~5~ potentiated A~2~ receptor signalling in neostriatal slices in a process in which mitogen-activated protein kinase (ERK) pathway seems to participate but not a synergism at the second messenger level \[[@r43], [@r44]\].

3.3. Functional Cross-talk through other Intracellular Proteins {#sec3.3}
---------------------------------------------------------------

The interaction of several GPCRs with specific proteins ('accessory proteins') can completely change their expression, function and fate. GPCRs themselves can also be accessory proteins when considering their homo- or heterodimers. Some of the main interacting proteins of GPCRs were reviewed elsewhere \[[@r73]\]. Adenosine and metabotropic glutamate receptors are also examples of GPCRs modulated by these interactions, and Table **[4](#T4){ref-type="table"}** summarizes several proposed linkers between the different receptors reviewed here. These linkers have been grouped according to their possible roles in receptor's crosstalk: cell surface expression, cytoskeletal linkage, G-protein coupling, GPCR regulation and GPCR degradation.

Adenosine deaminase (ADA) enzyme acts as a positive modulator of adenosine A~1~ and A~2A~ receptors, by enhancing their ligand affinity *via* conformational change \[[@r74]\]. Interestingly, ADA can interact with, and mediate the interaction between, A~1~ \[[@r75], [@r76]\], A~2A~ and A~2B~ receptors at the cell surface \[[@r77]\]. Moreover, binding of ADA to A~2B~ receptors increases the affinity of the agonist 5\'-N-ethylcarboxamidoadenosine and cAMP production \[[@r77]\]. In turn, the ER-associated 40-kDa heat shock protein family member D~1~ receptor interacting protein 78 (DRiP78) physically interacts and retain adenosine A~1~ receptor in ER, and negatively regulates the cell-surface expression of this adenosine receptor \[[@r78]\] avoiding its interaction with other GPCRs at the cell surface.

Homer protein homolog 1 (Homer 1) is a postsynaptic density scaffolding protein which binds and cross-links cytoplasmic regions of mGlu~1~ and mGlu~5~ \[[@r79], [@r80]\] and regulates the trafficking and surface expression of these receptors. By physically linking mGlu~1~ and mGlu~5~ with ER-associated ITPR1 receptors, Homer 1 aids the coupling of surface receptors to intracellular calcium release \[[@r81]\].

NHERF1-2 can bind Gα~q~-subunit, PLC and PKC, suggesting that NHERFs act as a scaffold protein bringing the effectors of the pathway together to facilitate the signal transmission. NHERF2 has also been shown to bind to the mGlu~5~ \[[@r82]\], where NHERF2 also potentiates the receptor-induced PLC activation, prolonging the intracellular Ca^2+^ mobilization. Moreover, NHERF1 and NHERF2 contribute to regulating the distribution of mGlu~2~ and mGlu~3~ in the murine brain \[[@r83]\].

Filamin-A (FLNA) promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signalling proteins. Some of these proteins are mGlu~4a~, mGlu~5a~, mGlu~5b~, mGlu~7a~, mGlu~7b~ and mGlu~8a~, where a conserved tyrosine within mGlu receptor carboxi termini mediates the binding to FLNA \[[@r84]\].

N-terminal EF-hand calcium-binding protein 2 (Necab2) may act as a signalling scaffold protein that senses intracellular calcium. The interaction of Necab2 with adenosine A~2A~ receptor modulates the cell surface expression, the ligand-dependent internalization and the receptor-mediated activation of the MAPK pathway \[[@r85]\]. Moreover, Necab2 modulates receptor function and coupling efficiency of mGlu~5~ by its physical interaction with this receptor \[[@r86]\].

Crosstalk between adenosine and metabotropic glutamate receptors can involve second-messengers dependent protein kinases. Thus, it is well known that in Central Nervous System, A~2A~ is coupled to G~s~ proteins, and stimulates the activity of adenylate cyclase which increases cyclic AMP production leading consequently to an increase in protein kinase A activity (PKA). It has also been described how PKA, by phosphorylating the aminoacid residue Ser870 located within the calmodulin binding site I in mGlu~5~, regulated the function of mGlu~5~ assayed as such as extracellular signal-regulated kinase phosphorylation and intracellular Ca^2+^ oscillations \[[@r87]\]. Finally, the participation of PKA in the crosstalk process between A~2A~ and mGlu~5~ has been shown in striatal slices where the facilitatory role of A~2A~ receptors on mGlu~5~-mediated responses was abolished by PKA inhibitor \[[@r46]\]. Interestingly, the same work also revealed that the participation of PKA seemed to be brain region-dependent since the synergism between the two receptors in hippocampal slices was resistant to PKA inhibitor \[[@r46]\].

Concerning group I mGluR, both receptor subtypes mGlu~1~ and mGlu~5~ are coupled in a positive way to phospholipase C through G~q~ proteins leading to triggering of inositol-1,4,5-trisphosphate (IP~3~)-mediated calcium release and to activation of protein kinase C (PKC). The ability of PKC to phosphorylate A~2A~ receptor has been shown in rat C6 glioma cells where the phosphorylation of receptors on three different aminoacid residues (Thr298, Ser320, and Ser335) was increased by pretreatment with PKC activator although no variations in A~2A~ receptor signalling were detected \[[@r88]\]. However, PKC has been suggested as participating in the synergism observed between group I mGlu and adenosine receptors in primary cultures of rat striatal neurons. Thus, in these cells, the potentiation of adenosine receptor responses observed upon group I mGlu receptors activation was abolished by a PKC inhibitor \[[@r89]\]. On the other hand, several works using rat hippocampal slices found that mGlu~1a~ receptor abolished A~1~ receptor-mediated responses in a process in which PKC seemed to be involved \[[@r41], [@r90], [@r91]\].

The functional effects cited above could be mediated by physical interactions with proteins such as calmodulin, GRP1 or Pick1, which together with PKC and PKA would contribute to GPCR regulation. Calmodulin (CaM) mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding. The carboxi terminal domain of mGlu~5~ and mGlu~7~ has been shown to bind to CaM \[[@r92], [@r93]\] and immobilized-CaM beads pulled down mGlu~3~, mGlu~4a~ and mGlu~7~ immunoreactivity from solubilized rat brain membranes in a Ca^2+^-dependent manner \[[@r94]\]. On mGlu~7~ only one CaM-binding site exists, whereas mGlu~5~ binds CaM at two distinct sites \[[@r95]\]. Moreover, CaM competes with the E3 ligase seven in absentia homolog (Siah)-1A for mGlu~5~ binding in a phosphorylation-dependent manner in rat hippocampal neurons, dynamically regulating mGlu~5~ trafficking \[[@r96]\]. In turn, CaM-binding to mGlu~7~ \[[@r93]\] overlaps the PKC phosphorylation site; thus calcium/CaM binding to the receptor inhibits PKC phosphorylation of mGlu~7~ \[[@r97]-[@r99]\]. It has been reported that CaM binds preferentially to a proximal C-terminus epitope of the adenosine A~2A~ receptor \[[@r100]\]. Thus, Ca^2+^ seems to induce conformational changes in the CaM-A~2A~-D~2~ receptor oligomer which leads to a selective modulation of MAPK signalling mediated by the A~2A~/D~2~ receptor heteromer \[[@r100]\]. A similar interaction could occur between A~2A~ and other mGlu receptors such as mGlu~5~.

General receptor for phosphoinositides 1-associated scaffold protein (GRP1-associated scaffold protein or GRASP) interacts with group I metabotropic glutamate receptors (mGlu~1~ and mGlu~5~). The yeast two-hybrid system and *in vitro* pull-down assays indicated that the PDZ ([P]{.ul}SD-95/[D]{.ul}lg1/[Z]{.ul}O-1) domain-containing, amino-terminal half of GRASP directly binds to the class I PDZ-binding motif of group I mGlu receptors \[[@r101]\]. The C-terminal half of GRASP also bound to cytohesins, the members of guanine nucleotide exchange factors (GEFs) specific for the ADP-ribosylation factor (ARF) family of small GTP-binding proteins. In turn, cytohesin-2 (Cyth2) interacts with the adenosine A~2A~ receptor \[[@r102]\] leading to the activation of mitogen-activated protein (MAP) kinase, *via* a pathway that is independent of heterotrimeric G proteins. Native mGlu~1a~/GRASP/cytohesin-2 complexes have also been coimmunoprecipitated from rat brain tissue \[[@r101]\].

MGlu~1a~ receptor signalling *via* InsP~3~ production induces the activation of PKC which, in turn, phosphorylates a threonine residue involved in receptor coupling to G~q/11~, resulting in the desensitization of mGlu~1a~ \[[@r103]\]. PKC is also involved in phosphorylation-dependent trafficking of mGlu~5~ \[[@r92], [@r96]\] and the phosphorylation of mGlu~7~ \[[@r104]\]. PKCα type (PKC-A) is a classical (or conventional) PKC activated by calcium and diacylglycerol in the presence of phosphatidylserine, and interacts with protein interacting with C-kinase (Pick1) *via* PDZ domain \[[@r105]\]. In addition, Pick1, a synaptic organizer protein, binds to the C terminus of mGlu~7a~ \[[@r104], [@r106]\] and mGlu~3~ \[[@r106]\]. Pick1 probably acts as an adapter protein that binds to and organizes the subcellular localization of a variety of membrane proteins containing some PDZ recognition sequence. In the agreement, Pick1 modulates PKCα-evoked phosphorylation of mGlu~7a~ and is involved in the clustering of various receptors, including mGlu~7~, at presynaptic release sites \[[@r107]\], possibly by acting at the receptor internalization level \[[@r104]\].

Apart from interactions with proteins that modulate GPCR cell surface expression, G-protein coupling, cell localization and regulation, other partners could mediate its trafficking and final degradation. Many GPCRs require posttranslational modification with ubiquitin and interaction with ubiquitin-binding domains of the endosomal-sorting complex required for transport (ESCRT) machinery for lysosomal sorting. In line with this, ubiquitin-C exists either covalently attached to another protein, or free (unanchored). When covalently bound, it is conjugated to target proteins *via* an isopeptide bond either as a monomer (monoubiquitin), a polymer linked *via* different Lys residues of the ubiquitin (polyubiquitin chains) or a linear polymer linked *via* the initiator Met of the ubiquitin (linear polyubiquitin chains). This binding of ubiquitin to an Lys residue determines different protein consequences on function (*e.g*. protein degradation). Quantitative Lys-ϵ-Gly-Gly (diGly) proteomics aimed to identify ubiquitin ligases substrates revealed the interaction of adenosine A~2B~ receptor with ubiquitin \[[@r108]\]. Similar proteomic approaches also revealed the interaction of ubiquitin with different plasma membrane receptors, including mGlu~5~ \[[@r109]\] and mGlu~7~ \[[@r110]\]. However, not all GPCRs require direct ubiquitination or all components of the ESCRT machinery for degradation in the lysosome, suggesting that alternate sorting pathways exist \[[@r111]\]. One of them is GPCR lysosomal sorting that is regulated by the G protein-coupled receptor associated sorting protein-1 (Gasp-1), which modulates lysosomal sorting and functional down-regulation of a variety of GPCRs. Gasp-1 targets receptors for degradation in lysosomes *via* its interaction with BECN2 \[[@r112]\] and interacts with cytoplasmic tails of a variety of GPCRs such as D~2~ and D~4~ dopamine receptors, delta opioid receptor 1 and beta-2 adrenergic receptor. Interestingly, Gasp-1 also interacts with carboxi terminal domains from mGlu~1a~, mGlu~5a~, and mGlu~8~ \[[@r113]\], probably contributing to the fate of these receptors in the cell.

Taken together, these functional and physical interactions with proteins cited above comprise the participation of cytoskeletal proteins and/or adaptor proteins that modify receptor localization, activation, trafficking and regulation, and participate in the *crosstalk* between these receptors.

4. NEW DRUG DESIGN POSSIBILITIES: TARGETING GPCR OLIGOMERS {#sec4}
==========================================================

According to previous paragraphs, GPCRs function is modulated through oligomer formation and protein-protein interactions. Therefore, a deeper knowledge about all these molecular interactions would be very helpful for the design of new, selective and therapeutically potent active drugs targeting these receptors, especially in the field of neurodegenerative disease \[[@r6]\]. Fine tuning of GPCR function through protein-protein interactions (*e.g*. homomerization or heteromerization) would comprise ligand interactions, cellular trafficking, and mobility \[[@r114], [@r115]\].

4.1. GPCR Homomerization can Modulate or Create new Binding Sites {#sec4.1}
-----------------------------------------------------------------

Besides the orthosteric site in a monomeric GPCR, the assembly of two monomers could result in new binding sites in the dimeric form of the receptor. In addition, when a ligand binds to the second protomer in a homodimer, it will often act as an allosteric modulator of the intrinsic efficacy of the ligand when binding to the first protomer \[[@r115]\]. Accordingly, it has been reported that adenosine A~1~ receptors form homomers not only in cell cultures but also in bovine brain cortex and that caffeine binding to one protomer increases the agonist affinity for the other protomer, a pharmacological characteristic that correlates with the low caffeine concentrations-induced activation of agonist-promoted A~1~ receptor signalling \[[@r116]\].

4.2. GPCR Heteromerization-mediated Transantagonism and Transactivation {#sec4.2}
-----------------------------------------------------------------------

In the heteromeric form, the activation (or blockade) of a GPCR could modulate the function of its partner. For instance, the stimulation of adenosine A~2A~ receptors decreases the affinity of dopamine D~2~ receptors in rat striatal membranes, where they heteromerize. This A~2A~/D~2~ heteromer may underlie the neuroleptic-like actions of adenosine agonists and the enhancing effects of adenosine antagonists on locomotor activity \[[@r117]\]. This heteromer represents the new concept of '*transantagonism'* when an oligomer interaction can occur in such a way that the activation of one receptor inhibits the signalling activity of the other. Another mechanism of *crosstalk* between GPCR heteromers would be '*transactivation'*, which occurs when the signalling cascade of one receptor is initiated upon an agonist binding to the other protomer \[[@r115]\]. These oligomers have been discussed as potential therapeutic targets for schizophrenia and/or Parkinson\'s disease as more specific alternatives to existing pharmaceuticals that target only the D~2~ monomer \[[@r118]\]. A~2A~/mGlu~5~ heteromer function also depends on the activation of one or both protomers. Thus, the stimulation of the mGlu~5~ receptor potentiates A~2A~ signalling in a MAPK-dependent manner in striatal slices \[[@r43]\] and could be mediated by the formation of A~2A~/mGlu~5~/D~2~ receptor heteromers \[[@r119]\]. An interesting possibility is the simultaneous activation of two different GPCRs, when heteromerized, through bivalent ligands, as has previously been evaluated in the case of A~1~/D~1~ \[[@r120]\], A~2A~/D~2~ \[[@r121]\] or μ opioid receptor/mGlu~5~ \[[@r122]\] heteromers.

4.3. GPCR Oligomerization-modulated G-protein Coupling {#sec4.3}
------------------------------------------------------

Finally, a potential result of GPCR oligomerization is the activation of different pathways from that activated by the monomeric state, for instance by novel G-protein coupling \[[@r123]\]. In line with this, the primary coupling of the group I mGluRs is with Gα~q/11~; however, these receptors can couple with Gα~s~ and Gα~i/o~ as well when overexpressed, probably forming receptor mosaics, in HEK293 and CHO cells \[[@r124]\]. Although the binding of two G proteins to a heterodimer seems not feasible due to steric clashes \[[@r125]\], the A~1~-A~2A~ heterotetramer (one A~1~ homodimer plus one A~2A~ homodimer)

may bind to both Gα~s~ and Gα~i~ proteins \[[@r126]\], suggesting receptor oligomerization dynamics as a crucial point in the determination of G-protein coupling and activation.

CONCLUSION
==========

From the previous paragraphs, we may draw some conclusions and lines of future research. Related to the envisaged work to do in the GPCR field, it seems mandatory: i) to develop new tools for the analysis of protein-protein interactions in the context of cell signalling, and ii) to improve the availability and accessibility of meaningful data through curated non-overlapping databases. To this end, it would be desirable to reduce the multiplicity of names used for the same protein/gene or for the same kind of data, and also to promote global initiatives similar to the above mentioned PSICQUIC. Finally, it is clear that signalling possibilities of a GPCR are not only limited to classical and linear signalling pathway activation (or blockade) but are impressively increased and diversified as a result of the variety of partners with which that GPCR could interact. The immediate consequence is the higher complexity that research on GPCR signalling deserves. But paradoxically, this difficulty should envisage an optimistic future as there would also be newer possibilities to target this GPCR in pathological status and disease.
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![Direct interaction network of adenosine receptors and group I metabotropic glutamate receptors. in *Homo sapiens* and *Rattus norvegicus*. Connecting lines between receptors (boxes) indicate the methodology (see insert) employed to assess such direct interaction as summarized in Table **3**. Green box: rat protein. Blue box: human protein. 3D structures were downloaded from Worldwide Protein Data Bank (<https://www.wwpdb.org>) \[[@r56]\] and they are summarized in Table **2**.](CN-17-422_F1){#F1}

###### 

List of consulted databases with corresponding webpage links (URL) and other available information such as number of interactions and version of database.

  **Name**            **Interactions**   **Version**   **URLs**
  ------------------- ------------------ ------------- --------------------------------------------
  APID Interactomes   1,225,163          1.1.5         <http://apid.dep.usal.es/>
  BAR                 115,325            1.3.13        <http://bar.utoronto.ca/>
  BindingDB           1,011,029          v1.3          <http://www.bindingdb.org>
  BioGrid             1,384,042          1.3.9         <http://www.thebiogrid.org>
  ChEMBL              628,504            1.2.7         <https://www.ebi.ac.uk/chembl/>
  DIP                 104,965            1.3           <http://dip.doe-mbi.ucla.edu/dip/Main.cgi>
  GPCR-HetNet         537                \-            <http://gpcr-hetnet.com/>
  HPIDb               4,763              1.3.13        <http://hpidb.igbb.msstate.edu/main.html>
  I2D                 817,915            1.1.6         <http://ophid.utoronto.ca/ophidv2.204/>
  IntAct              589,538            1.3.13        <https://www.ebi.ac.uk/intact/>
  iRefWeb             \-                 13.0          <http://wodaklab.org/iRefWeb/search/index>
  MatrixDB            1,342              1.3.13        <http://matrixdb.univ-lyon1.fr/>
  Mentha              1,144,545          \-            <http://mentha.uniroma2.it/>
  MINT                123,717            1.3.13        <http://mint.bio.uniroma2.it/>
  Reactome-FIs        209,988            1.2.7         <http://reactome.org/>
  STRING              1,380,838,440      10.5          <https://string-db.org/>
  UniProt             14,968             1.3.13        <http://www.uniprot.org/>
  ZINC                19,811             1.3.13        <http://zinc15.docking.org/>

###### 

List of gene and protein (Uniprot ID) names of receptors reviewed here. PDB: Protein Data Bank code is indicated only for the available experimental (not predicted by in silico modelling) 3D structure.

                                      ***Homo sapiens***   ***Rattus norvegicus***                             
  ----------------------------------- -------------------- ------------------------- ------ --------- -------- ------
  Adenosine receptor A~1~             ADORA1               P30542                    5N2S   Adora1    P25099   
  Adenosine receptor A~2A~            ADORA2A              P29274                    3EML   Adora2a   P30543   
  Adenosine receptor A~2B~            ADORA2B              P29275                           Adora2b   P29276   
  Adenosine receptor A~3~             ADORA3               P0DMS8                           Adora3    P28647   
  Metabotropic glutamate receptor 1   GRM1                 Q13255                    4OR2   Grm1      P23385   1EWK
  Metabotropic glutamate receptor 5   GRM5                 P41594                    4OO9   Grm5      P31424   

###### 

Experimentally determined protein-protein interactions in both *Homo sapiens* and *Rattus norvegicus* models. mGlu~N~: metabotropic glutamate receptor N. A~N~: adenosine A~N~ receptor. Empty cells: no data available.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                         **Protein A**                                                    **Protein B**                                            **Method**                                          **Interaction Type**                                             **Source**                                 **Publication**
  ------------------------------------------------------ ---------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------ ----------------------------------------
  ***Homo sapiens***                                     A~1~                                                             A~2A~                                                    anti tag coimmunoprecipitation                      within the same physical complex                                 IntAct (EBI-2904802)                       Ciruela *et al*., 2006 (PMID:16481441)

  anti tag coimmunoprecipitation                         within the same physical complex                                 IntAct (EBI-2904883)                                                                                                                                                                                                     

  bioluminescence resonance energy transfer              physical association                                             IntAct (EBI-2904906)                                                                                                                                                                                                     

  confocal microscopy                                    colocalization                                                   IntAct (EBI-2904959)                                                                                                                                                                                                     

  fluorescent resonance energy transfer                  oligomerization                                                  GPCR-HetNet                                              Schicker *et al*., 2009 (PMID:18973777)                                                                                                                         

  bioluminescence resonance energy transfer              oligomerization, in transfected HEK-293 cells                    GPCR-HetNet                                              Cristóvão-Ferreira *et al*., 2013 (PMID:23657626)                                                                                                               

  experimental knowledge based                                                                                                                                                     Wu *et al*., 2010 (PMID:20482850)                                                                                                                               

  A~3~                                                   radioligand binding                                              oligomerization                                          GPCR-HetNet                                         Hill *et al*., 2014 (PMID:24024783)                                                                         

  mGlu~1~                                                experimental knowledge based                                                                                                                                                  Wu *et al*., 2010 (PMID:20482850)                                                                           

  affinity chromatography technology                     physical association                                             BioGRID (302761)                                         Ciruela *et al*., 2001 (PMID:11278325)                                                                                                                          

  A~2A~                                                  A~2A~                                                            fluorescent resonance energy transfer                    physical association                                IntAct (EBI-8491775)                                             Vidi *et al*., 2008 (PMID:19013155)        

  bimolecular fluorescence complementation               physical association                                             IntAct (EBI-8491974)                                                                                                                                                                                                     

  bimolecular fluorescence complementation               physical association                                             IntAct (EBI-8492130)                                                                                                                                                                                                     

  fluorescent resonance energy transfer                  physical association                                             BioGRID (258280)                                         Kamiya *et al*., 2003 (PMID:12804599)                                                                                                                           

  bioluminescence resonance energy transfer              physical association                                             IntAct (EBI-8041827)                                     Gandia *et al*., 2008 (PMID:18675812)                                                                                                                           

  bioluminescence resonance energy transfer              physical association                                             IntAct (EBI-8041845)                                                                                                                                                                                                     

  bimolecular fluorescence complementation               physical association                                             IntAct (EBI-8041898)                                                                                                                                                                                                     

  affinity chromatography technology                     physical association                                             BioGRID (616424)                                         Burgueño *et al*., 2003 (PMID:12837758)                                                                                                                         

  mGlu~5~                                                fluorescent resonance energy transfer                            oligomerization, in transfected HEK-293 cells            GPCR-HetNet                                         Cabello *et al*., 2009 (PMID:19344374)                                                                      

  bimolecular fluorescence complementation                                                                                                                                                                                                                                                                                                         

  bioluminescence resonance energy transfer                                                                                                                                                                                                                                                                                                        

  pull down                                                                                                                                                                                                                                                                                                                                        

  A~3~                                                   A~3~                                                             radioligand binding                                      allosteric interaction                              PubMed                                                           May *et al*., 2011 (PMID:21715680)         

  mGlu~1~                                                mGlu~1~                                                          affinity chromatography technology                       physical association                                BioGRID (316750)                                                 Robbins *et al*., 1999 (PMID:10349865)     

  pull down                                              physical association                                             BioGRID (280937)                                         Ray *et al*., 2000 (PMID:10945991)                                                                                                                              

  x-ray crystallography                                  physical association                                             IntAct(EBI-9636453)                                      Wu *et al*., 2014 (PMID:24603153)                                                                                                                               

  two hybrid prey pooling approach                       molecular interaction                                            HPRD (Q13255)                                            Kitano *et al*., 2002 (PMID:11850456)                                                                                                                           

                                                         **Protein A**                                                    **Protein B**                                            **Method**                                          **Interaction Type**                                             **Source**                                 **Publication**

                                                         mGlu~5~                                                          mGlu~5~                                                  two hybrid prey pooling approach                    molecular interaction                                            HPRD (P41594)                              Kitano *et al*., 2002 (PMID:11850456)

  ***Rattus norvegicus***                                A~1~                                                             A~2A~                                                    electron microscopy                                 colocalization                                                   IntAct (EBI-2905139)                       Ciruela *et al*., 2006 (PMID:16481441)

  confocal microscopy                                    colocalization                                                   IntAct (EBI-2905272)                                                                                                                                                                                                     

  anti bait coimmunoprecipitation                        within the same physical complex                                 IntAct (EBI-2905309)                                                                                                                                                                                                     

  bioluminescence resonance\                             physical association, in primary\                                GPCR-HetNet                                              Cristóvão-Ferreira *et al*., 2013 (PMID:23657626)                                                                                                               
  energy transfer                                        cultures of astrocytes                                                                                                                                                                                                                                                                    

  A~2A~                                                  mGlu~5~                                                          anti bait coimmunoprecipitation                          within the same physical complex, in rat striatum   IntAct (EBI-2902881)                                             Ferré *et al*., 2002 (PMID:12189203)       

  fluorescent resonance energy transfer                  oligomerization, in rat striatum                                 GPCR-HetNet                                              Cabello *et al*., 2009 (PMID:19344374)                                                                                                                          

  bimolecular fluorescence complementation                                                                                                                                                                                                                                                                                                         

  bioluminescence resonance energy transfer                                                                                                                                                                                                                                                                                                        

  pull down                                                                                                                                                                                                                                                                                                                                        

  mGlu~1~                                                mGlu~1~                                                          mass spectrometry study of hydrogen/deuterium exchange   molecular interaction                               Bind (91134)                                                     Kunishima *et al*., 2000 (PMID:11069170)   

  fluorescent resonance energy transfer                  physical association                                             IntAct (EBI-7090108)                                     Rives *et al*., 2009 (PMID:19590495)                                                                                                                            

  bioluminescence resonance energy transfer              physical association                                             IntAct (EBI-7090497)                                                                                                                                                                                                     

  mGlu~5~                                                time-resolved fluorescence resonance energy transfer             physical association                                     PubMed                                              Goudet *et al*., 2005 (PMID:15863499)                                                                       

  time-resolved fluorescence resonance energy transfer   physical association                                             PubMed                                                   Doumazane *et al*., 2011 (PMID:20826542)                                                                                                                        

                                                         mGlu~5~ (rat)                                                    A~2A~ (human)                                            anti tag coimmunoprecipitation                      within the same physical complex, in transfected HEK-293 cells   IntAct (EBI-2902799)                       Ferré *et al*., 2002 (PMID:12189203)

  anti tag coimmunoprecipitation                         within the same physical complex, in transfected HEK-293 cells   IntAct (EBI-2902807)                                                                                                                                                                                                     

  confocal microscopy                                    colocalization, in transfected HEK-293 cells                     IntAct (EBI-2902730)                                                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Source: identification code for the specified interaction at the indicated database (Table **1**). PMID: PubMed ID for the cited reference.

###### 

Possible protein-linkers mediating adenosine and metabotropic glutamate receptors *crosstalk* at different levels, according to their possible roles in relation to GPCR function.

  **Role**                   **Possible Linker**           **Linked Proteins**              **Authors**                **PubMed ID**
  -------------------------- ----------------------------- -------------------------------- -------------------------- ---------------
  Cell surface expression    ADA                           A~1~                             Torvinen *et al*. (2002)   12150791
  Franco *et al*. (1997)     9247966                                                                                   
  A~2A~                      Herrera *et al*. (2001)       11125033                                                    
  A~2B~                                                                                                                
  DRiP78                     A~1~                          Málaga-Diéguez *et al*. (2010)   20219842                   
  Homer 1                    mGlu~1~                       Ango *et al*. (2001)             11418862                   
  Brakeman *et al*. (1997)   9069287                                                                                   
  Cytoeskeletal adapters     mGlu~5~                       Ango *et al*. (2001)             11418862                   
  Brakeman *et al*. (1997)   9069287                                                                                   
  Cyth2                      A~2A~                         Gsandtner *et al*. (2005)        16027149                   
  mGlu~1~                    Kitano *et al*. (2002)        11850456                                                    
  Efnb2                      mGlu~1~                       Caló *et al*. (2005)             15745950                   
  mGlu~5~                                                                                                              
  FLNA                       mGlu~5a~                      Enz *et al*. (2002)              11943148                   
  mGlu~5b~                                                                                                             
  Necab2                     A~2A~                         Canela *et al*. (2009)           19694902                   
  Canela *et al*. (2007)     17689978                                                                                  
  mGlu~5~                    Canela *et al*. (2009)        19694902                                                    
  NHERF1-2                   mGlu~5~                       Paquet *et al*. (2006)           16891310                   
  A~2B~                      Sitaraman *et al*. (2002)     12080047                                                    
  G protein coupling         Gα~o1~                        A~1~                             Waldhoer *et al*. (1999)   10521440
  mGlu~6~                    Dhingra *et al*. (2000)       11124982                                                    
  RGS12                      mGlu~1~                       Snow *et al*. (1998)             9651375                    
  mGlu~5~                                                                                                              
  G~βγ~                      A~1~                          Toms and Roberts, (1999)         10530813                   
  mGlu~1~                                                                                                              
  mGlu~5~                                                                                                              
  GPCR Regulation            CaM                           A~2A~                            Navarro *et al*. (2009)    19632986
  mGlu~5~                    Ko *et al*. (2012)            23152621                                                    
  Saugstad *et al*. (2002)   11953448                                                                                  
  Minakami *et al*. (1997)   9242710                                                                                   
  GRASP                      mGlu~1~                       Kitano *et al*. (2002)           11850456                   
  mGlu~5~                                                                                                              
  **Role**                   **Possible Linker**           **Linked Proteins**              **Authors**                **PubMed ID**
  GPCR Regulation            Pick1                         mGlu~1~                          Gan *et al*. (2016)        26946972
  mGlu~5~                                                                                                              
  PKA                        A~2A~                         Tebano *et al*. (2006)           18404464                   
  mGlu~5~                                                                                                              
  PKC                        mGlu~1~                       Francesconi *et al*. (2000)      10823959                   
  mGlu~5~                    Ko *et al*. (2012)            23152621                                                    
  Minakami *et al*. (1997)   9242710                                                                                   
  A~2~                       Cartmell *et al*. (1998)      9593890                                                     
  mGlu~1~                                                                                                              
  mGlu~5~                                                                                                              
  A~1~                       de Mendonça *et al*. (1997)   9283686                                                     
  mGlu~1~                                                                                                              
  mGlu~5~                                                                                                              
  A~1~                       Shahraki *et al*. (2003)      12684261                                                    
  mGlu~1~                                                                                                              
  GPCR Degradation           Gasp-1                        mGlu~1~                          Heydorn *et al*. (2004)    15452121
  mGlu~5~                                                                                                              
  Ubiquitin C                A~2B~                         Thompson *et al*. (2014)         25147182                   
  mGlu~5~                    Wagner *et al*. (2011)        21890473                                                    
